injection Novolog (Novo Nordisk) 28 days Prescribing information Insulin glargine (rDNA origin) vial or cartridge Lantus vial or cartridge (Sanofi-Aventis) 28 days Prescribing information 70% ...

Arkansas has become the latest US state to issue a legal challenge to the big three insulin producers – Eli Lilly, Sanofi and Novo Nordisk ... or $55 for five pen cartridges, adding that ...

The biosimilars – which will be interchangeable with Sanofi's Lantus (insulin glargine), Novo Nordisk's Novolog (insulin aspart) and Eli Lilly's Humalog ... box of five pen cartridges ...

In 2023, the global disposable pen injectors market is expected to be worth USD 25.5 billion. The market is expected to reach USD 54.4 billion by 2033, expanding at a 7.9% CAGR throughout the forecast ...

According to the American Diabetes Association, approximately 8.4 million people in the United States need insulin to survive ...

With Wegovy now playing catch-up and CagriSema failing to shake up the game, Novo is staring down a serious challenge from Lilly, which is running away with the weight-loss drug crown. So ...

Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the ...

With Wegovy now playing catch-up and CagriSema failing to shake up the game, Novo is staring down a serious challenge from Lilly, which is running away with the weight-loss drug crown. So, what's next ...

Trump has threatened to impose "very high" tariffs on Denmark if it doesn't sell Greenland to the U.S. These tariffs could cause the prices of Novo Nordisk's diabetes and obesity drugs to increase.

Founded a century ago, Copenhagen-based Nordisk originally made insulin. After coming to ... drug is currently in the works by Novo Nordisk, Eli Lilly, and several other rivals.